BFEC
RUBY

Benjamin F. Edwards & Company’s Rubius Therapeutics, Inc RUBY Stock Holding History

Benjamin F. Edwards & Company’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-525
Closed -$8K – 2008
2019
Q2 		$8K Sell
525
-800
-60% -$12.9K ﹤0.01% 1502
2019
Q1 		$24K Buy
1,325
+1,000
+308% +$15.3K ﹤0.01% 1089
2018
Q4 		$5K Buy
+325
New +$5.92K ﹤0.01% 1485

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Benjamin F. Edwards & Company's RUBY Position: Q3 2019 in Review

Benjamin F. Edwards & Company sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2019, closing a stake of 525 shares — an estimated $8K sold.

Benjamin F. Edwards & Company first reported a position in RUBY in Q4 2018 and held it in 3 quarters. The position peaked at $24K in Q1 2019. 75 funds tracked by Wall St. Rank hold RUBY as of Q3 2019.

  • Benjamin F. Edwards & Company reported no remaining Rubius Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 525 Rubius Therapeutics, Inc shares in Q3 2019, an estimated $8K.
  • Benjamin F. Edwards & Company first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 3 quarters.
  • Benjamin F. Edwards & Company's Rubius Therapeutics, Inc position peaked at $24K in Q1 2019.
  • 75 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2019, filed 5 Nov 2019.